NVS up +0.81% percent right now. $NVS High is at 9
Post# of 53479
Posted On: 11/10/2014 3:42:05 PM
NVS up +0.81% percent right now. $NVS High is at 92.64 and the Low 91.89 with current volume of 373,720.
Recent News posted below.
NVS Novartis Ag Recent Headline News
Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014
Marketwire Canada - 1 hr 37 mins ago
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced financial results for its third quarter ending September 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
TRX.VN: 0.530 (+0.010), NVS: 92.60 (+0.84)
Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020
M2 - Mon Nov 10, 10:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/r5npxt/nonhodgkin) has announced the addition of the "Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020" report to their offering. The approval of Rituxan (rituximab) has caused the size of the Non-Hodgkin Lymphoma (NHL) market to increase dramatically over the last two decades. This growth is expected to continue at a moderate pace during the forecast period, from $5.6 billion in 2013 culminating in revenues of $9.2 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 7.4%, in the major developed markets. In 2013, the major share of the global NHL market was attributed to by the US, representing 53% of the overall NHL market and this dominance is expected to be retained throughout the forecast period. The increasing uptake of new targeted therapies, especially novel small molecule inhibitors in the relapsed and refractory setting, along with the dominant usage of Rituxan is expected to fuel market growth in all the major developed markets. The expected launches of premium-priced novel antibodies and small molecule inhibitors, especially protein kinase inhibitors, targeting both indolent and aggressive sub-types of NHLs will widen the treatment population eligible for novel targeted and immunotherapies. The anticipated approval of promising pipeline drug candidates, Roche's obinutuzumab, Novartis' Afinitor (everolimus), Takeda's alisertib and Biovest's BiovaxID (dasiprotimut T) and GlaxoSmithKline's Arzerra (ofatumumab) for various NHL subtypes is a key driver for the steady increase in NHL market size. Despite of a flurry of expected launches, the growth in market is not anticipated to grow rapidly, particularly due to loss of patent exclusivity of Rituxan during the forecast period. Recently Launched Targeted and Immunotherapies has Widened Treatment Alternatives for Specific Sub-types Over the past two decades, significant progress has been made in the development of new therapies for NHL. Perhaps the most important milestone is the addition of Rituxan, approved by the US Food and Drug Administration (FDA) for relapsed or refractory Cluster of Differentiation (CD) 20-positive B-cell lymphoma in 1997. Following the approval of Rituxan in 1997, the US FDA approved five other monoclonal Antibodies (mAbs): Campath (alemtuzumab) in 2001, Bexxar (tositumomab) in 2003, Zevalin (ibritumomab tiuxetan) in 2002, Arzerra in 2009, and Adcetris (brentuximab vedotin) in 2011. Another novel mAb, mogamulizumab, which is still in Phase III clinical trials in the US, has already gained approval in Japan. The majority of these drugs are approved for the treatment of specific NHL sub-types. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products 4 Pipeline Products 5 Market Forecast to 2020 6 Deals and Strategic Consolidations 7 Appendix For more information visit http://www.researchandmarkets.com/research/r5npxt/nonhodgkin
NVS: 92.60 (+0.84)
Earnings Look Back: Novartis Is Down 0.6% Since Reporting Quarterly Results 1 Week Ago (NVS)
Comtex SmarTrend(R) - Mon Nov 10, 10:49AM CST
When Novartis (NYSE:NVS) reported earnings a week ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $1.30 on sales of $14.5 billion. The company actually reported a break-even quarter on sales of $13.0 billion, missing EPS estimates by $1.30 and missing revenue estimates by $14,504.5 billion. Shares of Novartis have slipped from $92.35 to $91.76, representing a loss of 0.6%, since the company reported earnings 13 days ago.
NVS: 92.60 (+0.84)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.63 (-0.03), CRIS: 1.30 (unch), IMMU: 3.71 (+0.10), PCYC: 133.88 (+0.39), ONCY: 0.81 (+0.11), PFE: 30.23 (+0.31), LLY: 68.37 (+1.77), BMY: 58.67 (+0.35), GSK: 45.20 (+0.29), JNJ: 108.79 (+0.59), SNTA: 3.10 (-0.04), NVS: 92.60 (+0.84), XLRN: 32.16 (+1.97), ARRY: 3.88 (unch), CELGZ: 3.13 (-0.11), EXEL: 1.79 (+0.05)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.63 (+0.03), IMGN: 9.94 (+0.17), AMGN: 163.12 (+2.87), LLY: 68.37 (+1.77), ONTX: 4.86 (+0.08), BMY: 58.67 (+0.35), GSK: 45.20 (+0.29), OXGN: 1.98 (-0.18), XLRN: 32.16 (+1.97), KPTI: 42.96 (+0.82), NVS: 92.60 (+0.84)
Novartis to present secukinumab Phase 3 data next week
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:21AM CST
NVS: 92.60 (+0.84)
Is this MannKind Corporation's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 10, 7:32AM CST
The commercial success or failure of a new drug is rarely the result of a single event. So, predicting how a drug will perform prior to launch is perhaps more guesswork than most experts will openly admit. For example, after an arduous back and forth...
LLY: 68.37 (+1.77), GSK: 45.20 (+0.29), MNKD: 5.86 (+0.08), NVS: 92.60 (+0.84)
3 Drugs That Make Gilead Sciences' Harvoni Look Cheap
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 10, 6:31AM CST
Source: Bill Brooks/Flickr Healthcare costs are the leading cause of bankruptcy, so it's little wonder that people are up in arms over the cost of newly launched medicine like Gilead Sciences Harvoni. Gilead set the price of a 12-week...
GILD: 106.95 (+0.50), BMY: 58.67 (+0.35), NVS: 92.60 (+0.84)
Novartis to present first IL-17A Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
PR Newswire - Mon Nov 10, 6:00AM CST
Novartis announced today that data from two pivotal Phase III studies (FUTURE 1 and FUTURE 2) in psoriatic arthritis (PsA) patients and two pivotal Phase III studies (MEASURE 1 and MEASURE 2) in patients with ankylosing spondylitis (AS) will be presented at the American College of Rheumatology (ACR) Congress, November 14-19, in Boston. The four oral presentations and four posters measure efficacy and symptom improvement in PsA and AS patients treated with AIN457 (secukinumab). US regulatory applications of secukinumab in PsA and AS are planned to be submitted in 2015.
NVS: 92.60 (+0.84)
New Report Reveals Most Leading Pharma Companies Still Not Commercially Ready for Personalized Medicine Business Model
Marketwired - Mon Nov 10, 4:00AM CST
Diaceutics (www.diaceutics.com) today released the four year update to its Pharma Readiness for Personalized Medicine Report, which examines how prepared leading pharmaceutical companies are for the emerging personalized medicine (PM) business model.
NVS: 92.60 (+0.84)
Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
Thomson Reuters ONE - Mon Nov 10, 12:16AM CST
Novartis International AG / Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 92.60 (+0.84)
Google's "Cancer Pill": Revolutionary or Ridiculous?
Leo Sun, The Motley Fool - Motley Fool - Sun Nov 09, 1:24PM CST
Google recently unveiled one of its most ambitious healthcare projects ever -- a "smart pill" which scans for cancer cells and other health problems. The pill is loaded with nanoparticles, which are roughly 1/2,000th the size of a red blood cell,...
ABBV: 63.82 (+2.32), GOOGL: 559.01 (+7.19), GOOG: 548.36 (+7.35), ORCL: 40.43 (+0.49), NVS: 92.60 (+0.84)
Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 195.59 (-0.41), ABBV: 63.82 (+2.32), BMY: 58.67 (+0.35), NVS: 92.60 (+0.84)
Ad Comm votes against panobinostat
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 11:53AM CST
NVS: 92.60 (+0.84)
Novartis announces outcome of FDA advisory committee meeting for multiple myeloma investigational compound LBH589
Thomson Reuters ONE - Thu Nov 06, 11:41AM CST
Novartis International AG / Novartis announces outcome of FDA advisory committee meeting for multiple myeloma investigational compound LBH589 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 92.60 (+0.84)
Leiomyosarcoma - Pipeline Review, H2 2014 - 3 Companies & 7 Drug Profiles
M2 - Thu Nov 06, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/p9hmg6/leiomyosarcoma) has announced the addition of the "Leiomyosarcoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Leiomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leiomyosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Novartis AG - Karyopharm Therapeutics, Inc. Drug Profiles - everolimus - pazopanib hydrochloride - Cell Therapy 3 for Oncology - Cell Therapy 2 for Oncology and Infectious Disease - selinexor - Cell Therapy for Oncology and Infectious Diseases - NOV-110501 For more information visit http://www.researchandmarkets.com/research/p9...myosarcoma
GSK: 45.20 (+0.29), NVS: 92.60 (+0.84), KPTI: 42.96 (+0.82)
Metastatic Uveal Melanoma Therapeutics Pipeline Review, H2 2014 - 5 Companies & 7 Drug Profiles
M2 - Thu Nov 06, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/23f5jr/metastatic_uveal) has announced the addition of the "Metastatic Uveal Melanoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Uveal Melanoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Novartis AG - Spectrum Pharmaceuticals, Inc. Drug Profiles - selumetinib sulfate - vincristine sulfate - trametinib dimethyl sulfoxide uprosertib - LY-2801653 - sotrastaurin acetate - binimetinib - emibetuzumab For more information visit http://www.researchandmarkets.com/research/23...atic_uveal
AZN: 73.28 (+0.40), SPPI: 7.46 (+0.13), LLY: 68.37 (+1.77), GSK: 45.20 (+0.29), NVS: 92.60 (+0.84)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.23 (+0.31), INCY: 70.73 (+1.41), ONTX: 4.86 (+0.08), BMY: 58.67 (+0.35), GSK: 45.20 (+0.29), STML: 14.96 (+0.34), SNTA: 3.10 (-0.04), KBIO: 1.94 (+0.14), BPTH: 2.88 (-0.09), CELGZ: 3.13 (-0.11), NVS: 92.60 (+0.84)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 327.78 (+7.03), PCYC: 133.90 (+0.41), PSTI: 2.65 (-0.01), NBS: 4.91 (+0.06), ALDR: 16.86 (+0.29), IDRA: 2.53 (+0.10), SGEN: 36.58 (+0.53), JAZZ: 174.73 (+3.93), ALXN: 195.51 (+1.70), KMDA: 3.86 (-0.29), ATHX: 1.52 (-0.01), NVS: 92.60 (+0.84)
Recent News posted below.
NVS Novartis Ag Recent Headline News
Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014
Marketwire Canada - 1 hr 37 mins ago
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced financial results for its third quarter ending September 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). TRX.VN: 0.530 (+0.010), NVS: 92.60 (+0.84)
Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020
M2 - Mon Nov 10, 10:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/r5npxt/nonhodgkin) has announced the addition of the "Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020" report to their offering. The approval of Rituxan (rituximab) has caused the size of the Non-Hodgkin Lymphoma (NHL) market to increase dramatically over the last two decades. This growth is expected to continue at a moderate pace during the forecast period, from $5.6 billion in 2013 culminating in revenues of $9.2 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 7.4%, in the major developed markets. In 2013, the major share of the global NHL market was attributed to by the US, representing 53% of the overall NHL market and this dominance is expected to be retained throughout the forecast period. The increasing uptake of new targeted therapies, especially novel small molecule inhibitors in the relapsed and refractory setting, along with the dominant usage of Rituxan is expected to fuel market growth in all the major developed markets. The expected launches of premium-priced novel antibodies and small molecule inhibitors, especially protein kinase inhibitors, targeting both indolent and aggressive sub-types of NHLs will widen the treatment population eligible for novel targeted and immunotherapies. The anticipated approval of promising pipeline drug candidates, Roche's obinutuzumab, Novartis' Afinitor (everolimus), Takeda's alisertib and Biovest's BiovaxID (dasiprotimut T) and GlaxoSmithKline's Arzerra (ofatumumab) for various NHL subtypes is a key driver for the steady increase in NHL market size. Despite of a flurry of expected launches, the growth in market is not anticipated to grow rapidly, particularly due to loss of patent exclusivity of Rituxan during the forecast period. Recently Launched Targeted and Immunotherapies has Widened Treatment Alternatives for Specific Sub-types Over the past two decades, significant progress has been made in the development of new therapies for NHL. Perhaps the most important milestone is the addition of Rituxan, approved by the US Food and Drug Administration (FDA) for relapsed or refractory Cluster of Differentiation (CD) 20-positive B-cell lymphoma in 1997. Following the approval of Rituxan in 1997, the US FDA approved five other monoclonal Antibodies (mAbs): Campath (alemtuzumab) in 2001, Bexxar (tositumomab) in 2003, Zevalin (ibritumomab tiuxetan) in 2002, Arzerra in 2009, and Adcetris (brentuximab vedotin) in 2011. Another novel mAb, mogamulizumab, which is still in Phase III clinical trials in the US, has already gained approval in Japan. The majority of these drugs are approved for the treatment of specific NHL sub-types. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products 4 Pipeline Products 5 Market Forecast to 2020 6 Deals and Strategic Consolidations 7 Appendix For more information visit http://www.researchandmarkets.com/research/r5npxt/nonhodgkin
NVS: 92.60 (+0.84)
Earnings Look Back: Novartis Is Down 0.6% Since Reporting Quarterly Results 1 Week Ago (NVS)
Comtex SmarTrend(R) - Mon Nov 10, 10:49AM CST
When Novartis (NYSE:NVS) reported earnings a week ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $1.30 on sales of $14.5 billion. The company actually reported a break-even quarter on sales of $13.0 billion, missing EPS estimates by $1.30 and missing revenue estimates by $14,504.5 billion. Shares of Novartis have slipped from $92.35 to $91.76, representing a loss of 0.6%, since the company reported earnings 13 days ago.
NVS: 92.60 (+0.84)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.63 (-0.03), CRIS: 1.30 (unch), IMMU: 3.71 (+0.10), PCYC: 133.88 (+0.39), ONCY: 0.81 (+0.11), PFE: 30.23 (+0.31), LLY: 68.37 (+1.77), BMY: 58.67 (+0.35), GSK: 45.20 (+0.29), JNJ: 108.79 (+0.59), SNTA: 3.10 (-0.04), NVS: 92.60 (+0.84), XLRN: 32.16 (+1.97), ARRY: 3.88 (unch), CELGZ: 3.13 (-0.11), EXEL: 1.79 (+0.05)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.63 (+0.03), IMGN: 9.94 (+0.17), AMGN: 163.12 (+2.87), LLY: 68.37 (+1.77), ONTX: 4.86 (+0.08), BMY: 58.67 (+0.35), GSK: 45.20 (+0.29), OXGN: 1.98 (-0.18), XLRN: 32.16 (+1.97), KPTI: 42.96 (+0.82), NVS: 92.60 (+0.84)
Novartis to present secukinumab Phase 3 data next week
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:21AM CST
NVS: 92.60 (+0.84)
Is this MannKind Corporation's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Mon Nov 10, 7:32AM CST
The commercial success or failure of a new drug is rarely the result of a single event. So, predicting how a drug will perform prior to launch is perhaps more guesswork than most experts will openly admit. For example, after an arduous back and forth...
LLY: 68.37 (+1.77), GSK: 45.20 (+0.29), MNKD: 5.86 (+0.08), NVS: 92.60 (+0.84)
3 Drugs That Make Gilead Sciences' Harvoni Look Cheap
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 10, 6:31AM CST
Source: Bill Brooks/Flickr Healthcare costs are the leading cause of bankruptcy, so it's little wonder that people are up in arms over the cost of newly launched medicine like Gilead Sciences Harvoni. Gilead set the price of a 12-week...
GILD: 106.95 (+0.50), BMY: 58.67 (+0.35), NVS: 92.60 (+0.84)
Novartis to present first IL-17A Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
PR Newswire - Mon Nov 10, 6:00AM CST
Novartis announced today that data from two pivotal Phase III studies (FUTURE 1 and FUTURE 2) in psoriatic arthritis (PsA) patients and two pivotal Phase III studies (MEASURE 1 and MEASURE 2) in patients with ankylosing spondylitis (AS) will be presented at the American College of Rheumatology (ACR) Congress, November 14-19, in Boston. The four oral presentations and four posters measure efficacy and symptom improvement in PsA and AS patients treated with AIN457 (secukinumab). US regulatory applications of secukinumab in PsA and AS are planned to be submitted in 2015.
NVS: 92.60 (+0.84)
New Report Reveals Most Leading Pharma Companies Still Not Commercially Ready for Personalized Medicine Business Model
Marketwired - Mon Nov 10, 4:00AM CST
Diaceutics (www.diaceutics.com) today released the four year update to its Pharma Readiness for Personalized Medicine Report, which examines how prepared leading pharmaceutical companies are for the emerging personalized medicine (PM) business model.
NVS: 92.60 (+0.84)
Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
Thomson Reuters ONE - Mon Nov 10, 12:16AM CST
Novartis International AG / Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 92.60 (+0.84)
Google's "Cancer Pill": Revolutionary or Ridiculous?
Leo Sun, The Motley Fool - Motley Fool - Sun Nov 09, 1:24PM CST
Google recently unveiled one of its most ambitious healthcare projects ever -- a "smart pill" which scans for cancer cells and other health problems. The pill is loaded with nanoparticles, which are roughly 1/2,000th the size of a red blood cell,...
ABBV: 63.82 (+2.32), GOOGL: 559.01 (+7.19), GOOG: 548.36 (+7.35), ORCL: 40.43 (+0.49), NVS: 92.60 (+0.84)
Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 195.59 (-0.41), ABBV: 63.82 (+2.32), BMY: 58.67 (+0.35), NVS: 92.60 (+0.84)
Ad Comm votes against panobinostat
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 11:53AM CST
NVS: 92.60 (+0.84)
Novartis announces outcome of FDA advisory committee meeting for multiple myeloma investigational compound LBH589
Thomson Reuters ONE - Thu Nov 06, 11:41AM CST
Novartis International AG / Novartis announces outcome of FDA advisory committee meeting for multiple myeloma investigational compound LBH589 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 92.60 (+0.84)
Leiomyosarcoma - Pipeline Review, H2 2014 - 3 Companies & 7 Drug Profiles
M2 - Thu Nov 06, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/p9hmg6/leiomyosarcoma) has announced the addition of the "Leiomyosarcoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Leiomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leiomyosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Novartis AG - Karyopharm Therapeutics, Inc. Drug Profiles - everolimus - pazopanib hydrochloride - Cell Therapy 3 for Oncology - Cell Therapy 2 for Oncology and Infectious Disease - selinexor - Cell Therapy for Oncology and Infectious Diseases - NOV-110501 For more information visit http://www.researchandmarkets.com/research/p9...myosarcoma
GSK: 45.20 (+0.29), NVS: 92.60 (+0.84), KPTI: 42.96 (+0.82)
Metastatic Uveal Melanoma Therapeutics Pipeline Review, H2 2014 - 5 Companies & 7 Drug Profiles
M2 - Thu Nov 06, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/23f5jr/metastatic_uveal) has announced the addition of the "Metastatic Uveal Melanoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Uveal Melanoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Novartis AG - Spectrum Pharmaceuticals, Inc. Drug Profiles - selumetinib sulfate - vincristine sulfate - trametinib dimethyl sulfoxide uprosertib - LY-2801653 - sotrastaurin acetate - binimetinib - emibetuzumab For more information visit http://www.researchandmarkets.com/research/23...atic_uveal
AZN: 73.28 (+0.40), SPPI: 7.46 (+0.13), LLY: 68.37 (+1.77), GSK: 45.20 (+0.29), NVS: 92.60 (+0.84)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.23 (+0.31), INCY: 70.73 (+1.41), ONTX: 4.86 (+0.08), BMY: 58.67 (+0.35), GSK: 45.20 (+0.29), STML: 14.96 (+0.34), SNTA: 3.10 (-0.04), KBIO: 1.94 (+0.14), BPTH: 2.88 (-0.09), CELGZ: 3.13 (-0.11), NVS: 92.60 (+0.84)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 327.78 (+7.03), PCYC: 133.90 (+0.41), PSTI: 2.65 (-0.01), NBS: 4.91 (+0.06), ALDR: 16.86 (+0.29), IDRA: 2.53 (+0.10), SGEN: 36.58 (+0.53), JAZZ: 174.73 (+3.93), ALXN: 195.51 (+1.70), KMDA: 3.86 (-0.29), ATHX: 1.52 (-0.01), NVS: 92.60 (+0.84)
(0)
(0)Scroll down for more posts ▼